Cisplatin

CheckMate 9LA: TMB and immune checkpoint inhibitor efficacy 3:30
CheckMate 9LA: TMB and immune checkpoint inhibitor efficacy
Sanjay Popat • 31 Mar 2021
EV-201: enfortumab vedotin for cisplatin-ineligible bladder cancer 2:58
EV-201: enfortumab vedotin for cisplatin-ineligible bladder cancer
Arjun Balar • 18 Feb 2021
Mesothelioma: how will novel immunotherapies impact surgery? 4:06
Mesothelioma: how will novel immunotherapies impact surgery?
Eric Lim • 22 Mar 2021
The latest treatment options for BRCA-mutated breast cancer 4:24
The latest treatment options for BRCA-mutated breast cancer
Judy Garber • 15 Mar 2021
KEYNOTE-189 update: 4-year follow-up of FL pembro +chemo metastatic NSCLC 3:03
KEYNOTE-189 update: 4-year follow-up of FL pembro +chemo metastatic NSCLC
Nir Peled • 10 Feb 2021
Trial updates from ASCO GU 2021: SPIRE, NEO-BLADE, P3BEP and SAPROCAN 3:52
Trial updates from ASCO GU 2021: SPIRE, NEO-BLADE, P3BEP and SAPROCAN
Alison Birtle • 16 Feb 2021
INTACT: safety results of CRT with and without atezolizumab in MIBC 8:16
INTACT: safety results of CRT with and without atezolizumab in MIBC
Parminder Singh • 16 Feb 2021
Extended follow-up data from POUT in urothelial cancer 1:02
Extended follow-up data from POUT in urothelial cancer
Robert Jones • 15 Feb 2021
Association of response to first-line chemotherapy with atezolizumab efficacy in mUC 4:33
Association of response to first-line chemotherapy with atezolizumab efficacy in mUC
Deniz Tural • 14 Feb 2021
KEYNOTE-992: pembrolizumab plus chemoRT for MIBC 3:53
KEYNOTE-992: pembrolizumab plus chemoRT for MIBC
Andrew Weickhardt • 11 Feb 2021
KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC 3:03
KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC
Martin Reck • 1 Feb 2021
Updated results from the CASPIAN trial of durvalumab plus chemo in SCLC 1:43
Updated results from the CASPIAN trial of durvalumab plus chemo in SCLC
Robin Cornelissen • 18 Jan 2021
Gallbladder & bile duct cancer at ASCO GI: GAIN and other highlights 5:13
Gallbladder & bile duct cancer at ASCO GI: GAIN and other highlights
Thorsten Goetze • 22 Jan 2021
LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA 1:52
LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA
Rachna T. Shroff • 7 Jan 2021
Phase III study of NUC-1031 for first-line treatment of CCA 1:28
Phase III study of NUC-1031 for first-line treatment of CCA
Rachna T. Shroff • 7 Jan 2021
Optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing? 4:34
Optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?
Arlene Siefker-Radtke • 14 Oct 2020
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals